Clinical trial
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
NCT00463385 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00463385 |
|---|---|
| Title | A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia |
| Official title | A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With… |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis |
| Intervention type | Drug |
| Interventions | Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone |
| Enrollment | 88 |
| Start date | Apr 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | Dec 31, 2013 |
| First posted | Apr 20, 2007 |
| Last update posted | Nov 20, 2019 |
| Countries | Austria, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: